{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:26:34Z","timestamp":1789269994133,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many studies have revealed that mucosal healing improves the long-term prognosis of ulcerative colitis. Frequent colonoscopy is difficult because of its invasiveness and cost. Therefore, in diagnosing and treating ulcerative colitis, noninvasive, low-cost methods for predicting mucosal healing using useful biomarkers are required in the clinical setting.<\/jats:p>\n                    <jats:p>This study aimed to evaluate whether serum amyloid A is a better serum biomarker than C-reactive protein in predicting mucosal healing in ulcerative colitis patients in clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ulcerative colitis patients whose C-reactive protein and serum amyloid A were measured within 1\u2009month before and after colonoscopy were included in this retrospective study, and the relationship between the C-reactive protein and serum amyloid A values and the mucosal condition was analyzed. Mucosal condition was assessed using the Mayo Endoscopic Score, with score 0 or 1 indicating mucosal healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 199 colonoscopic examinations were conducted in 108 ulcerative colitis patients who underwent C-reactive protein and serum amyloid A blood tests. In clinical remission patients, serum amyloid A showed a strong correlation with mucosal inflammation compared to C-reactive protein and had excellent sensitivity and specificity rates with significant statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum amyloid A is a more useful marker compared to C-reactive protein in predicting mucosal inflammation in ulcerative colitis patients in clinical remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01229-8","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T06:07:53Z","timestamp":1585894073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission"],"prefix":"10.1186","volume":"20","author":[{"given":"Masaki","family":"Wakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713\u201325.","journal-title":"N Engl J Med"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","volume":"141","author":"JF Colombel","year":"2011","unstructured":"Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194\u2013201.","journal-title":"Gastroenterology"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","volume":"07","author":"E Langholz","year":"1994","unstructured":"Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;07:3\u201311.","journal-title":"Gastroenterology"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrgastro.2009.203","volume":"7","author":"G Pineton de Chamburn","year":"2010","unstructured":"Pineton de Chamburn G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15\u201329.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","volume":"12","author":"EA Fagan","year":"1982","unstructured":"Fagan EA, Dyck RF, Maton PN, et al. Serum level of C-reactive protein in Crohn\u2019s disease and ulcerative colitis. Eur J Clin Investig. 1982;12:351\u20139.","journal-title":"Eur J Clin Investig"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448\u201354.","journal-title":"N Engl J Med"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1373\/clinchem.2003.028258","volume":"50","author":"AJ MacGregor","year":"2004","unstructured":"MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem. 2004;50:130\u20134.","journal-title":"Clin Chem"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jcp.36.7.798","volume":"36","author":"JG Raynes","year":"1983","unstructured":"Raynes JG, Cooper EH. Comparison of serum amyloid a protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol. 1983;36:798\u2013803.","journal-title":"J Clin Pathol"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1365-2362.1987.tb01143.x","volume":"17","author":"RE Chambers","year":"1987","unstructured":"Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid a protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Investig. 1987;17:460\u20137.","journal-title":"Eur J Clin Investig"},{"key":"1229_CR10","first-page":"90","volume":"44","author":"C Niederau","year":"1997","unstructured":"Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn\u2019s disease and ulcerative colitis. Hepatogastroenterology. 1997;44:90\u2013107.","journal-title":"Hepatogastroenterology"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989;298:82\u20136.","journal-title":"BMJ"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/gutjnl-2014-308839","volume":"64","author":"C Manginot","year":"2015","unstructured":"Manginot C, Baumann C, Peyrin-Biroulet L. An endoscopic Mayo of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut. 2015;64:1181\u20132.","journal-title":"Gut"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ecco-jcc\/jjv158","volume":"10","author":"M Barreiro-de Acosta","year":"2016","unstructured":"Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bast\u00f3n I, Ferreiro-Iglesias R, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohn Colitis. 2016;10:13\u20139.","journal-title":"J Crohn Colitis"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1590-8658(03)00381-5","volume":"35","author":"F Costa","year":"2003","unstructured":"Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as a non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642\u20137.","journal-title":"Dig Liver Dis"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1111\/j.1572-0241.2000.03194.x","volume":"95","author":"PJ Limburg","year":"2000","unstructured":"Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1229_CR18","first-page":"26","volume":"9","author":"A Lasson","year":"2015","unstructured":"Lasson A, Stotzer PO, \u00d6hman O, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26\u201332.","journal-title":"J Crohns Colitis"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/cs0680233","volume":"68","author":"CP Maury","year":"1985","unstructured":"Maury CP. Comparative study of serum amyloid a protein and C-reactive protein in disease. Clin Sci. 1985;68:233\u20138.","journal-title":"Clin Sci"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.dld.2017.12.010","volume":"50","author":"S Ishihara","year":"2018","unstructured":"Ishihara S, Tada Y, Kawashima K, Kataoka M, Sonoyama H, Yamashita N, et al. Serum amyloid a level correlated with endoscopic findings in patients with Crohn\u2019s disease\u2013possible biomarker for evaluating mucosal healing. Dig Liver Dis. 2018;50:553\u20138.","journal-title":"Dig Liver Dis"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1471-230X-10-133","volume":"10","author":"RM Erik","year":"2010","unstructured":"Erik RM. Eckhardt, Jassir Witta, Jian Zhong et al. intestinal epithelial serum amyloid a modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis. BMC Gastroenterol. 2010;10:133.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-01229-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T19:18:58Z","timestamp":1617391138000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01229-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01229-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our study protocol conformed to the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Declaration of Helsinki in 1964 and later versions and was approved by the Institutional Review Board of Hiroshima University Hospital. In this study, we only used clinical information without invasion or intervention to the patient, and we disclosed information such as research implementation and purpose and secured participants\u2019 opportunity to refuse participation through posters.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}